According to treatment recommendations from the European LeukemiaNet and the National Comprehensive Cancer Network, patients with high-risk polycythemia vera (PV) should receive cytoreductive medication together with standard treatments for low-risk PV: phlebotomy and low-dose aspirin.
According to treatment recommendations from the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network, patients with high-risk polycythemia vera (PV) should receive cytoreductive medication together with standard treatments for low-risk PV: phlebotomy and low-dose aspirin.
A recent retrospective cohort study sought to assess whether high-risk patients are in fact receiving guideline-concordant treatment, and used claims data from the Truven Health MarketScan database to analyze the claims of 1823 high-risk and 1033 low-risk patients with PV. The index date for the study was January 1, 2013, approximately 2 years after publication of the ELN guidelines, and records were assessed for the preindex period (beginning January 1, 2012) through the postindex period (spanning from January 1, 2013, to December 31, 2014).
Read more about polycythemia vera.
In the preindex period, 36.5% of high-risk patients and 15.5% of low-risk patients received cytoreductive drugs. The most common preindex therapies used were hydroxyurea (94.7% and 87.5% in the high- and low-risk groups, respectively), anagrelide (7.4% and 11.9%, respectively), and interferon (1.7% and 4.4%, respectively).
Among patients who received no cytoreductive therapies in the preindex period, 6.7% initiated such therapies in the postindex period. Of these patients, 74.1% were high-risk, and 25.9% were low-risk. In total, 42.0% of patients with high-risk disease and 18.9% of patients with low-risk disease received cytoreductive drugs at any time assessed.
Those who did not receive cytoreductive medicine preindex had more phlebotomies than those who did receive medication (43.3% versus 37.3%), and this trend was similar between high- and low-risk groups.
The investigators concluded that the majority of high-risk patients with PV do not receive cytoreductive medication, despite treatment guidelines.
“Given the increased mortality of patients with PV compared with age-matched subjects without PV, the present data suggest that a considerable proportion of patients with high-risk PV would likely benefit from revised treatment plans that align with current clinical guideline recommendations,” they said.
Reference
Paranagama D, Colucci P, Evans KA, Bonafede M, Parasuraman S. Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. 2018;7(16). doi: 10.1186/s40164-018-0107-8.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More